Guanylate cyclase-C agonists

Introduction

Guanylate cyclase-C (GC-C) agonists are a relatively new class of gastrointestinal agents that have emerged as targeted therapies for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). These drugs represent a mechanistic leap in the treatment of functional bowel disorders by addressing the pathophysiology at the level of intestinal epithelial cell receptors. Unlike traditional osmotic or stimulant laxatives, which broadly influence bowel function through mechanical or irritant effects, GC-C agonists operate through receptor-mediated activation of natural intestinal secretory pathways, closely mimicking endogenous peptides such as uroguanylin and guanylin.

Currently, the two primary GC-C agonists approved for clinical use are linaclotide and plecanatide, marketed under the brand names Linzess and Trulance, respectively. Both agents share a similar mechanism of action but differ slightly in peptide structure, dosing regimens, and pH sensitivity, which influences their site of maximal activity along the gastrointestinal tract.

---

Brand Names and Active Ingredients

1. Linaclotide

   • Brand name: Linzess

   • Formulation: Oral capsules

   • Active ingredient: Linaclotide (synthetic 14-amino acid peptide)

   • Manufacturer: Ironwood Pharmaceuticals in collaboration with Allergan/AbbVie (U.S. market)

2. Plecanatide

   • Brand name: Trulance

   • Formulation: Oral tablets

   • Active ingredient: Plecanatide (synthetic 16-amino acid peptide)

   • Manufacturer: Synergy Pharmaceuticals (later acquired by Bausch Health)

Both linaclotide and plecanatide are minimally absorbed peptides, designed to act locally in the lumen of the gastrointestinal tract. Their structures are analogues of naturally occurring intestinal peptides, allowing them to bind to GC-C receptors with high affinity while having negligible systemic exposure.

---

Mechanism of Action

GC-C agonists exert their pharmacological effects by binding to and activating the guanylate cyclase-C receptor, a transmembrane receptor-enzyme located on the apical (luminal) surface of intestinal epithelial cells.

Step-by-Step Mechanism:

1. Binding to GC-C receptors

   • Linaclotide and plecanatide mimic the activity of endogenous ligands—guanylin and uroguanylin—by binding to GC-C receptors in the small intestine and colon.

2. Conversion of GTP to cGMP

   • Upon activation, GC-C catalyzes the conversion of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP), a second messenger.

3. Stimulation of CFTR channels

   • Elevated intracellular cGMP activates protein kinase G II (PKG II), which in turn phosphorylates and activates the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel.

4. Secretion of chloride and bicarbonate

   • The activated CFTR channels secrete chloride (Cl⁻) and bicarbonate (HCO₃⁻) ions into the intestinal lumen. Sodium ions follow to maintain electrochemical neutrality, and water follows osmotically.

5. Increased intestinal fluid and accelerated transit

   • The influx of water into the lumen softens stool, increases stool volume, and accelerates intestinal transit time.

6. Reduction of visceral pain

   • In addition to secretory effects, GC-C activation increases extracellular (basolateral) cGMP release into the submucosal space. This modulates sensory neurons in the enteric nervous system, decreasing afferent nerve firing and reducing visceral hypersensitivity, which is a hallmark of IBS-C.

Key Mechanistic Points:

• Local action: GC-C agonists act locally in the GI tract without significant systemic absorption, minimizing systemic side effects.

• pH sensitivity: Plecanatide is most active in a more neutral pH environment (like uroguanylin), while linaclotide is active over a broader pH range.

• Dual benefit: In IBS-C, the drugs address both constipation and abdominal discomfort/pain.

---

Therapeutic Uses

1. Chronic Idiopathic Constipation (CIC)

   • CIC is characterized by infrequent bowel movements, straining, hard stools, and a sensation of incomplete evacuation without a secondary cause.

   • GC-C agonists improve bowel movement frequency, soften stools, and reduce straining by increasing intestinal secretion.

2. Irritable Bowel Syndrome with Constipation (IBS-C)

   • IBS-C is a subtype of IBS characterized by abdominal pain/discomfort associated with constipation.

   • GC-C agonists relieve constipation and significantly reduce abdominal pain through their anti-nociceptive effects.

3. Investigational/Off-label uses (under clinical study)

   • Functional constipation in pediatric patients (research ongoing, not currently approved for children under 18 years)

   • Potential role in opioid-induced constipation (early studies have examined effects, but not approved indication)

---

Dosage and Administration

Linaclotide (Linzess)

• CIC in adults: 145 mcg orally once daily, on an empty stomach, at least 30 minutes before the first meal of the day.

• IBS-C in adults: 290 mcg orally once daily, same administration timing.

• Lower dose option: Some patients with CIC may respond to 72 mcg once daily (approved in the U.S. for those sensitive to diarrhea).

• Administration notes:

  • Swallow capsules whole; do not break or chew.

  • For patients unable to swallow, capsule contents may be mixed with applesauce or water and taken immediately.

Plecanatide (Trulance)

• CIC and IBS-C in adults: 3 mg orally once daily, with or without food.

• Administration notes:

  • Tablets can be swallowed whole or crushed and mixed with applesauce or water for patients with swallowing difficulty.

---

Contraindications

• Known or suspected mechanical gastrointestinal obstruction: Activation of intestinal secretion and motility in obstructed patients may lead to serious complications.

• Pediatric patients under 6 years: Animal studies show increased risk of severe dehydration; human data confirm risk.

• Avoid in pediatric patients aged 6–17 years: Not recommended due to dehydration risk; safety and efficacy not established.

---

Side Effects

Common Adverse Effects (incidence varies by agent and indication)

• Diarrhea: Most common; can be mild to moderate.

• Abdominal pain

• Flatulence

• Bloating

• Abdominal distension

• Urgency

Less Common Adverse Effects

• Nausea

• Vomiting

• Headache

• Dizziness

• Fatigue

• Upper respiratory tract infection (observed in some studies)

Serious Adverse Effects

• Severe diarrhea leading to dehydration, hypotension, dizziness, syncope, electrolyte imbalances; may require discontinuation and supportive therapy.

---

Precautions

1. Severe diarrhea risk: Discontinue therapy if severe diarrhea occurs.

2. Dehydration risk: Elderly, debilitated, or those with low fluid intake are at higher risk.

3. Pregnancy: No adequate human data; animal studies show adverse fetal effects at high doses. Use only if benefits outweigh risks.

4. Lactation: Not known if excreted in human milk; minimal systemic absorption makes significant exposure unlikely, but caution is advised.

5. Pediatric safety: Not established in under 18 years; contraindicated under 6 years.

6. Swallowing difficulties: Both drugs can be given with specific food or liquid preparations if patients cannot swallow whole dosage forms.

---

Drug Interactions

Because GC-C agonists have negligible systemic absorption, traditional systemic pharmacokinetic interactions are rare. However, certain pharmacodynamic considerations apply:

1. Concomitant use with laxatives or pro-secretory agents

   • May increase risk and severity of diarrhea.

2. Impact on oral drug absorption

   • Severe diarrhea may reduce gastrointestinal transit time, potentially reducing the absorption and efficacy of other oral medications.

3. Electrolyte disturbances

   • Persistent diarrhea can cause dehydration and electrolyte imbalance, which may alter the pharmacokinetics of other drugs (especially those with narrow therapeutic indices such as digoxin, lithium, or antiarrhythmics).

---

Pharmacokinetics

• Absorption: Minimal to no systemic absorption; peptides are degraded within the gastrointestinal tract.

• Distribution: No significant systemic distribution.

• Metabolism: Proteolytic degradation to smaller peptides and amino acids within the gut.

• Excretion: Fecal elimination of degraded products.

The lack of systemic absorption is a major advantage, as it limits systemic toxicity and drug–drug interactions.

---

Comparative Notes Between Linaclotide and Plecanatide

Feature	Linaclotide (Linzess)	Plecanatide (Trulance)
Peptide length	14 amino acids	16 amino acids
Origin	Analog of guanylin	Analog of uroguanylin
Optimal pH for activity	Broad range	Neutral to slightly acidic
Dosing	72 mcg, 145 mcg, or 290 mcg once daily	3 mg once daily
Administration	Empty stomach, 30 min before meal	With or without food
FDA approval	2012	2017

Clinical Efficacy Evidence

Linaclotide

• Multiple phase III trials in IBS-C and CIC have demonstrated significant improvements in bowel movement frequency, stool consistency, and reduction of abdominal pain compared with placebo.

• Abdominal pain scores and quality-of-life measures showed statistically significant improvement in IBS-C patients.

Plecanatide

• Trials in CIC and IBS-C patients have shown similar efficacy to linaclotide with a potentially slightly lower incidence of diarrhea, though cross-trial comparisons are limited.

• Shares the same endpoint improvements: spontaneous bowel movements (SBM), complete SBMs, stool softness, and pain reduction.

---

Practical Prescribing Considerations

• Patient selection: Best suited for adults with moderate to severe CIC or IBS-C who have not responded to conventional therapies (fiber supplementation, osmotic laxatives).

• Onset of action: Some patients notice improvements within the first week, though full effect may require several weeks.

• Adherence: Stress importance of daily dosing; missing doses may reduce symptom control.

• Hydration: Encourage adequate fluid intake to minimize dehydration risk.

---

Safety Monitoring

• Monitor for frequency and severity of diarrhea.

• Assess hydration status in at-risk populations.

• Evaluate for any signs of gastrointestinal obstruction before initiating therapy.

• Reassess need for continued therapy periodically based on symptom control and tolerability.